Fennec Pharma(FENC)
搜索文档
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates
ZACKS· 2024-08-13 20:26
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -433.33%. A quarter ago, it was expected that this company would post earnings of $0.49 per share when it actually produced earnings of $0.41, delivering a surprise of -16.33%. Over the last four quarters, the company has ...
Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire News Room· 2024-08-13 18:05
~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $43 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial res ...
Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024
GlobeNewswire News Room· 2024-08-07 04:31
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2024 financial results and provide a business update before the opening of the U.S. financial markets on Tuesday, August 13, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast De ...
Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024
Newsfilter· 2024-08-07 04:31
文章核心观点 - 芬尼克制药公司将于2024年8月13日发布2024年第二季度财务业绩报告并提供业务更新[1] - 公司将参加2024年8月13-14日在纽约举行的2024年Wedbush PacGrow医疗保健会议[3] - 公司专注于开发和商业化PEDMARK®和Pedmarqsi,以降低白金类化疗药物导致的儿童患者听力损害风险[4] - PEDMARK已于2022年9月获得FDA批准,2023年6月获得欧盟市场准入授权,并获得7年的市场独占权[4] 财务业绩报告 - 公司将于2024年8月13日发布2024年第二季度财务业绩报告[1] - 公司将在当天举行电话会议和网络直播,讨论公司的财务和业务情况[1][2] 会议参与 - 公司将参加2024年8月13-14日在纽约举行的2024年Wedbush PacGrow医疗保健会议[3]
Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director
GlobeNewswire News Room· 2024-08-05 18:26
~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr. Jeff Hackman as its Chief Executive Officer (CEO) ...
Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director
Newsfilter· 2024-08-05 18:26
文章核心观点 - 芬尼克制药公司任命Jeff Hackman为新任首席执行官,接替Rosty Raykov [3][4][7] - Jeff Hackman拥有30多年商业领导经验,在肿瘤学领域有12年从业经历,擅长新疗法的商业化推广 [5] - 芬尼克公司的主要产品PEDMARK®和Pedmarqsi®获得美国和欧洲批准,用于减少儿童癌症患者接受顺铂化疗导致的永久性听力损失风险 [8] 公司概况 - 芬尼克制药公司是一家专注于PEDMARK®和Pedmarqsi®开发和商业化的专科制药公司 [8] - PEDMARK®在美国获得7年市场独占权,Pedmarqsi®在欧洲获得8年加2年的数据和市场保护 [8] - 公司拥有来自俄勒冈健康科学大学的专利许可,用于治疗顺铂化疗引起的耳毒性 [8] 行业概况 - PEDMARK®和Pedmarqsi®是目前唯一获批用于减少儿童癌症患者顺铂化疗导致永久性听力损失风险的治疗方法 [2][4] - 这种治疗方法对于改善患者生活质量具有重要意义 [7]
Fennec Pharmaceuticals Announces Management Change
Newsfilter· 2024-07-01 18:00
RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec's Chief Operating Officer as of June 30, 2024. After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership team as Chief Operating Officer. "We are grateful to Adrian for joining Fennec's leadership team at such a critical point in ...
Fennec Pharmaceuticals Announces Management Change
GlobeNewswire News Room· 2024-07-01 18:00
RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024. After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership team as Chief Operating Officer. “We are grateful to Adrian for joining Fennec’s leadership team at such a critical point ...
Fennec Announces Results of Annual Meeting
Newsfilter· 2024-06-26 04:35
RESEARCH TRIANGLE PARK, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the "Company") (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 29, 2024 (the "Circular") for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in New York, New York on June 25, 2024. Detailed results of the vote for the election of directors are set out below: Name of Nom ...
Fennec Announces Results of Annual Meeting
GlobeNewswire News Room· 2024-06-26 04:35
RESEARCH TRIANGLE PARK, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 29, 2024 (the “Circular”) for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in New York, New York on June 25, 2024. Detailed results of the vote for the election of directors are set out below: Name of Nom ...